{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:58Z","timestamp":1786979938816,"version":"build-2736575974"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00277-025-06304-2","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T22:26:23Z","timestamp":1741818383000},"page":"1415-1426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["TIGIT\/PVR axis regulates anti-tumor immunity in hematologic malignancies"],"prefix":"10.1007","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0174-2906","authenticated-orcid":false,"given":"Fanqiao","family":"Meng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maoyuan","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfeng","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"6304_CR1","doi-asserted-by":"publisher","unstructured":"Tsumura A, Levis D, Tuscano JM (2023) Checkpoint inhibition in hematologic malignancies. Front Oncol; 13: 1288172. e-pub ahead of print 2023\/11\/03; https:\/\/doi.org\/10.3389\/fonc.2023.1288172","DOI":"10.3389\/fonc.2023.1288172"},{"key":"6304_CR2","doi-asserted-by":"publisher","unstructured":"Borgeaud M, Sandoval J, Obeid M, Banna G, Michielin O, Addeo A et al (2023) Novel targets for immune-checkpoint inhibition in cancer. Cancer Treat Rev; 120: 102614. e-pub ahead of print 2023\/08\/21; https:\/\/doi.org\/10.1016\/j.ctrv.2023.102614","DOI":"10.1016\/j.ctrv.2023.102614"},{"issue":"12","key":"6304_CR3","doi-asserted-by":"publisher","first-page":"3057","DOI":"10.1158\/1078-0432.CCR-15-2626","volume":"22","author":"Y Kong","year":"2016","unstructured":"Kong Y, Zhu L, Schell TD, Zhang J, Claxton DF, Ehmann WC et al (2016) T-Cell Immunoglobulin and ITIM domain (TIGIT) associates with CD8\u2009+\u2009T-Cell exhaustion and poor clinical outcome in AML patients. Clin Cancer Res 22(12):3057\u20133066. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-2626. e-pub ahead of print 2016\/01\/15","journal-title":"Clin Cancer Res"},{"key":"6304_CR4","doi-asserted-by":"publisher","unstructured":"Stamm H, Klingler F, Grossjohann EM, Muschhammer J, Vettorazzi E, Heuser M et al (2018) Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option. Oncogene; 37(39): 5269\u20135280. e-pub ahead of print 2018\/06\/02; https:\/\/doi.org\/10.1038\/s41388-018-0288-y","DOI":"10.1038\/s41388-018-0288-y"},{"key":"6304_CR5","doi-asserted-by":"publisher","unstructured":"Jin Z, Ye W, Lan T, Zhao Y, Liu X, Chen J et al (2020) Characteristic of TIGIT and DNAM-1 Expression on Foxp3\u2009+\u2009gammadelta T Cells in AML Patients. Biomed Res Int; 2020: 4612952. e-pub ahead of print 2020\/08\/18; https:\/\/doi.org\/10.1155\/2020\/4612952","DOI":"10.1155\/2020\/4612952"},{"key":"6304_CR6","doi-asserted-by":"publisher","unstructured":"Ge MJ, Xu KL, Xu T, Tang YN, Li ZY, Yan ZL et al (2020) [Expression and Significance of PD-1, TIM-3 and VISTA on T Cell of Acute Myeloid Leukemia Patients]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 28(3): 748\u2013752. e-pub ahead of print 2020\/06\/20; https:\/\/doi.org\/10.19746\/j.cnki.issn.1009-2137.2020.03.006","DOI":"10.19746\/j.cnki.issn.1009-2137.2020.03.006"},{"issue":"2","key":"6304_CR7","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1111\/ajco.13236","volume":"16","author":"Y Chen","year":"2020","unstructured":"Chen Y, Tan J, Huang S, Huang X, Huang J, Chen J et al (2020) Higher frequency of the CTLA-4(+) LAG-3(+) T-cell subset in patients with newly diagnosed acute myeloid leukemia. Asia Pac J Clin Oncol 16(2):e12\u2013e18 e-pub ahead of print 2019\/10\/16. https:\/\/doi.org\/10.1111\/ajco.13236","journal-title":"Asia Pac J Clin Oncol"},{"key":"6304_CR8","doi-asserted-by":"publisher","unstructured":"Li W, Blessin NC, Simon R, Kluth M, Fischer K, Hube-Magg C et al (2018) Expression of the immune checkpoint receptor TIGIT in Hodgkin\u2019s lymphoma. BMC Cancer; 18(1): 1209. e-pub ahead of print 2018\/12\/06; https:\/\/doi.org\/10.1186\/s12885-018-5111-1","DOI":"10.1186\/s12885-018-5111-1"},{"key":"6304_CR9","doi-asserted-by":"publisher","unstructured":"Josefsson SE, Beiske K, Blaker YN, Forsund MS, Holte H, Ostenstad B et al (2019) TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma. Cancer Immunol Res; 7(3): 355\u2013362. e-pub ahead of print 2019\/01\/20; https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0351","DOI":"10.1158\/2326-6066.CIR-18-0351"},{"issue":"6","key":"6304_CR10","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR et al (2014) Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28(6):1280\u20131288 e-pub ahead of print 2013\/11\/26. https:\/\/doi.org\/10.1038\/leu.2013.355","journal-title":"Leukemia"},{"issue":"51","key":"6304_CR11","doi-asserted-by":"publisher","first-page":"88904","DOI":"10.18632\/oncotarget.21492","volume":"8","author":"T Asayama","year":"2017","unstructured":"Asayama T, Tamura H, Ishibashi M, Kuribayashi-Hamada Y, Onodera-Kondo A, Okuyama N et al (2017) Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes. Oncotarget 8(51):88904\u201388917 e-pub ahead of print 2017\/11\/29. https:\/\/doi.org\/10.18632\/oncotarget.21492","journal-title":"Oncotarget"},{"key":"6304_CR12","doi-asserted-by":"publisher","unstructured":"Guillerey C, Harjunpaa H, Carrie N, Kassem S, Teo T, Miles K et al (2018) TIGIT immune checkpoint blockade restores CD8(+) T-cell immunity against multiple myeloma. Blood; 132(16): 1689\u20131694. e-pub ahead of print 2018\/07\/11; https:\/\/doi.org\/10.1182\/blood-2018-01-825265","DOI":"10.1182\/blood-2018-01-825265"},{"key":"6304_CR13","doi-asserted-by":"publisher","unstructured":"Tremblay-LeMay R, Rastgoo N, Chang H, Modulating (2018) PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1\/PD-L1 pathway. J Hematol Oncol; 11(1): 46. e-pub ahead of print 2018\/03\/28; https:\/\/doi.org\/10.1186\/s13045-018-0589-1","DOI":"10.1186\/s13045-018-0589-1"},{"key":"6304_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.critrevonc.2017.01.011","volume":"111","author":"SH Jung","year":"2017","unstructured":"Jung SH, Lee HJ, Vo MC, Kim HJ, Lee JJ (2017) Immunotherapy for the treatment of multiple myeloma. Crit Rev Oncol Hematol 111:87\u201393 e-pub ahead of print 2017\/03\/06. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.01.011","journal-title":"Crit Rev Oncol Hematol"},{"key":"6304_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2017.04.001","volume":"81","author":"Y He","year":"2017","unstructured":"He Y, Peng H, Sun R, Wei H, Ljunggren HG, Yokoyama WM et al (2017) Contribution of inhibitory receptor TIGIT to NK cell education. J Autoimmun 81:1\u201312. https:\/\/doi.org\/10.1016\/j.jaut.2017.04.001. e-pub ahead of print 2017\/04\/26","journal-title":"J Autoimmun"},{"issue":"2","key":"6304_CR16","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cei.13407","volume":"200","author":"H Harjunpaa","year":"2020","unstructured":"Harjunpaa H, Guillerey C (2020) TIGIT as an emerging immune checkpoint. Clin Exp Immunol 200(2):108\u2013119 e-pub ahead of print 2019\/12\/13. https:\/\/doi.org\/10.1111\/cei.13407","journal-title":"Clin Exp Immunol"},{"key":"6304_CR17","doi-asserted-by":"publisher","unstructured":"Gorvel L, Olive D (2020) Targeting the PVR-TIGIT axis with immune checkpoint therapies. F1000Res; 9. e-pub ahead of print 2020\/06\/04; https:\/\/doi.org\/10.12688\/f1000research.22877.1","DOI":"10.12688\/f1000research.22877.1"},{"key":"6304_CR18","doi-asserted-by":"publisher","unstructured":"Fourcade J, Sun Z, Chauvin JM, Ka M, Davar D, Pagliano O et al (2018) CD226 opposes TIGIT to disrupt Tregs in melanoma. JCI Insight 3(14). https:\/\/doi.org\/10.1172\/jci.insight.121157. e-pub ahead of print 2018\/07\/27","DOI":"10.1172\/jci.insight.121157"},{"key":"6304_CR19","doi-asserted-by":"publisher","unstructured":"Stein N, Tsukerman P, Mandelboim O (2017) The paired receptors TIGIT and DNAM-1 as targets for therapeutic antibodies. Hum Antibodies 25(3\u20134) 111\u2013119. e-pub ahead of print 2016\/12\/31. https:\/\/doi.org\/10.3233\/HAB-160307","DOI":"10.3233\/HAB-160307"},{"key":"6304_CR20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.clim.2017.08.021","volume":"190","author":"M Wang","year":"2018","unstructured":"Wang M, Bu J, Zhou M, Sido J, Lin Y, Liu G et al (2018) CD8(+)T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients. Clin Immunol 190:64\u201373 e-pub ahead of print 2017\/09\/13. https:\/\/doi.org\/10.1016\/j.clim.2017.08.021","journal-title":"Clin Immunol"},{"key":"6304_CR21","doi-asserted-by":"publisher","unstructured":"Zhu L, Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB et al (2017) Blimp-1 impairs T cell function via upregulation of TIGIT and PD-1 in patients with acute myeloid leukemia. J Hematol Oncol; 10(1): 124. e-pub ahead of print 2017\/06\/21; https:\/\/doi.org\/10.1186\/s13045-017-0486-z","DOI":"10.1186\/s13045-017-0486-z"},{"key":"6304_CR22","doi-asserted-by":"publisher","unstructured":"Naghavi Alhosseini M, Palazzo M, Cari L, Ronchetti S, Migliorati G, Nocentini G (2023) Overexpression of potential markers of regulatory and exhausted CD8(+) T cells in the peripheral blood mononuclear cells of patients with B-Acute lymphoblastic leukemia. Int J Mol Sci 24(5) e-pub ahead of print 2023\/03\/12. https:\/\/doi.org\/10.3390\/ijms24054526","DOI":"10.3390\/ijms24054526"},{"key":"6304_CR23","doi-asserted-by":"publisher","unstructured":"Duy C, Beguelin W, Melnick A (2020) Epigenetic mechanisms in leukemias and lymphomas. Cold Spring Harb Perspect Med 10(12). https:\/\/doi.org\/10.1101\/cshperspect.a034959. e-pub ahead of print 2020\/02\/06","DOI":"10.1101\/cshperspect.a034959"},{"issue":"9","key":"6304_CR24","first-page":"2690","volume":"10","author":"Z Dlamini","year":"2020","unstructured":"Dlamini Z, Shoba B, Hull R (2020) Splicing machinery genomics events in acute myeloid leukaemia (AML): in search for therapeutic targets, diagnostic and prognostic biomarkers. Am J Cancer Res 10(9):2690\u20132704 e-pub ahead of print 2020\/10\/13;","journal-title":"Am J Cancer Res"},{"key":"6304_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM (2019) Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev 36:70\u201387 e-pub ahead of print 2019\/05\/19. https:\/\/doi.org\/10.1016\/j.blre.2019.04.005","journal-title":"Blood Rev"},{"issue":"4","key":"6304_CR26","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jgo.2017.12.002","volume":"9","author":"MR Luskin","year":"2018","unstructured":"Luskin MR, Abel GA (2018) Management of older adults with myelodysplastic syndromes (MDS). J Geriatr Oncol 9(4):302\u2013307. https:\/\/doi.org\/10.1016\/j.jgo.2017.12.002. e-pub ahead of print 2018\/01\/02","journal-title":"J Geriatr Oncol"},{"key":"6304_CR27","doi-asserted-by":"publisher","first-page":"619","DOI":"10.2147\/CIA.S196087","volume":"15","author":"KL Schoenbeck","year":"2020","unstructured":"Schoenbeck KL, Wildes TM (2020) Updated perspectives on the management of multiple myeloma in older patients: focus on Lenalidomide. Clin Interv Aging 15:619\u2013633 e-pub ahead of print 2020\/05\/23. https:\/\/doi.org\/10.2147\/CIA.S196087","journal-title":"Clin Interv Aging"},{"key":"6304_CR28","doi-asserted-by":"publisher","unstructured":"Khan Z, Agarwal NB, Bhurani D, Khan MA (2020) Risk Factors for Hematopoietic Stem Cell Transplantation-Associated Bone Loss. Biol Blood Marrow Transplant e-pub ahead of print 2020\/10\/13; https:\/\/doi.org\/10.1016\/j.bbmt.2020.10.002","DOI":"10.1016\/j.bbmt.2020.10.002"},{"issue":"2","key":"6304_CR29","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/MOH.0000000000000562","volume":"27","author":"DM Swoboda","year":"2020","unstructured":"Swoboda DM, Gesiotto Q, Sallman DA (2020) Novel therapies in myelodysplastic syndromes. Curr Opin Hematol 27(2):58\u201365 e-pub ahead of print 2020\/01\/24. https:\/\/doi.org\/10.1097\/MOH.0000000000000562","journal-title":"Curr Opin Hematol"},{"key":"6304_CR30","doi-asserted-by":"publisher","unstructured":"Platzbecker U (2019) Treatment of MDS. Blood; 133(10): 1096\u20131107. e-pub ahead of print 2019\/01\/24; https:\/\/doi.org\/10.1182\/blood-2018-10-844696","DOI":"10.1182\/blood-2018-10-844696"},{"issue":"4","key":"6304_CR31","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11899-020-00573-6","volume":"15","author":"S Arslan","year":"2020","unstructured":"Arslan S, Nakamura R (2020) Decision analysis of transplantation for patients with myelodysplasia: who should we transplant today?? Curr Hematol Malig Rep 15(4):305\u2013315 e-pub ahead of print 2020\/03\/31. https:\/\/doi.org\/10.1007\/s11899-020-00573-6","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"6304_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s15006-022-2180-5","volume":"165","author":"M Lukas","year":"2023","unstructured":"Lukas M (2023) [Recent advances in the treatment of myelodysplastic syndromes (MDS)]. MMW Fortschr Med 165(1):43\u201345 e-pub ahead of print 2023\/01\/18. https:\/\/doi.org\/10.1007\/s15006-022-2180-5","journal-title":"MMW Fortschr Med"},{"key":"6304_CR33","doi-asserted-by":"publisher","unstructured":"Noh JY, Seo H, Lee J, Jung H (2020) Immunotherapy in hematologic malignancies: emerging therapies and novel approaches. Int J Mol Sci 21(21). https:\/\/doi.org\/10.3390\/ijms21218000. e-pub ahead of print 2020\/10\/31","DOI":"10.3390\/ijms21218000"},{"key":"6304_CR34","doi-asserted-by":"publisher","unstructured":"Huang J, Huang X, Huang J (2022) CAR-T cell therapy for hematological malignancies: Limitations and optimization strategies. Front Immunol; 13: 1019115. e-pub ahead of print 2022\/10\/18; https:\/\/doi.org\/10.3389\/fimmu.2022.1019115","DOI":"10.3389\/fimmu.2022.1019115"},{"key":"6304_CR35","doi-asserted-by":"publisher","first-page":"100991","DOI":"10.1016\/j.blre.2022.100991","volume":"57","author":"Y Serroukh","year":"2023","unstructured":"Serroukh Y, Hebert J, Busque L, Mercier F, Rudd CE, Assouline S et al (2023) Blasts in context: the impact of the immune environment on acute myeloid leukemia prognosis and treatment. Blood Rev 57:100991. https:\/\/doi.org\/10.1016\/j.blre.2022.100991. e-pub ahead of print 2022\/08\/09","journal-title":"Blood Rev"},{"issue":"2","key":"6304_CR36","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/MOH.0000000000000749","volume":"30","author":"AM Brunner","year":"2023","unstructured":"Brunner AM (2023) Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia. Curr Opin Hematol 30(2):38\u201344 e-pub ahead of print 2023\/02\/03. https:\/\/doi.org\/10.1097\/MOH.0000000000000749","journal-title":"Curr Opin Hematol"},{"key":"6304_CR37","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/978-3-319-40320-5_11","volume":"169","author":"S Lonial","year":"2016","unstructured":"Lonial S (2016) Treatment of MM: upcoming novel therapies. Cancer Treat Res 169:195\u2013205. https:\/\/doi.org\/10.1007\/978-3-319-40320-5_11. e-pub ahead of print 2016\/10\/04","journal-title":"Cancer Treat Res"},{"key":"6304_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26853","author":"I Aldoss","year":"2023","unstructured":"Aldoss I, Shah BD, Park JH, Muffly L, Logan AC, Brown P et al (2023) Sequencing antigen-targeting antibodies and cellular therapies in adults with relapsed\/refractory B-cell acute lymphoblastic leukemia. Am J Hematol. e-pub ahead of print 2023\/01\/25 https:\/\/doi.org\/10.1002\/ajh.26853","journal-title":"Am J Hematol"},{"key":"6304_CR39","doi-asserted-by":"publisher","unstructured":"Jin S, Zhang Y, Zhou F, Chen X, Sheng J, Zhang J (2022) TIGIT: A promising target to overcome the barrier of immunotherapy in hematological malignancies. Front Oncol; 12: 1091782. e-pub ahead of print 2023\/01\/07; https:\/\/doi.org\/10.3389\/fonc.2022.1091782","DOI":"10.3389\/fonc.2022.1091782"},{"issue":"42","key":"6304_CR40","doi-asserted-by":"publisher","first-page":"17858","DOI":"10.1073\/pnas.0903474106","volume":"106","author":"N Stanietsky","year":"2009","unstructured":"Stanietsky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A et al (2009) The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci U S A 106(42):17858\u201317863 e-pub ahead of print 2009\/10\/10. https:\/\/doi.org\/10.1073\/pnas.0903474106","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6304_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.semcancer.2019.11.013","volume":"65","author":"JS O\u2019Donnell","year":"2020","unstructured":"O\u2019Donnell JS, Madore J, Li XY, Smyth MJ (2020) Tumor intrinsic and extrinsic immune functions of CD155. Semin Cancer Biol 65:189\u2013196 e-pub ahead of print 2019\/12\/31. https:\/\/doi.org\/10.1016\/j.semcancer.2019.11.013","journal-title":"Semin Cancer Biol"},{"key":"6304_CR42","doi-asserted-by":"publisher","unstructured":"Qiu D, Liu X, Wang W, Jiang X, Wu X, Zheng J et al (2022) TIGIT axis: novel immune checkpoints in anti-leukemia immunity. Clin Exp Med e-pub ahead of print 2022\/04\/15; https:\/\/doi.org\/10.1007\/s10238-022-00817-0","DOI":"10.1007\/s10238-022-00817-0"},{"key":"6304_CR43","doi-asserted-by":"publisher","unstructured":"Sanchez-Correa B, Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Bergua JM et al (2019) DNAM-1 and the TIGIT\/PVRIG\/TACTILE axis: novel immune checkpoints for natural killer Cell-Based Cancer immunotherapy. Cancers (Basel) 11(6) e-pub ahead of print 2019\/06\/27. https:\/\/doi.org\/10.3390\/cancers11060877","DOI":"10.3390\/cancers11060877"},{"issue":"8","key":"6304_CR44","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.4049\/jimmunol.1103627","volume":"188","author":"E Lozano","year":"2012","unstructured":"Lozano E, Dominguez-Villar M, Kuchroo V, Hafler DA (2012) The TIGIT\/CD226 axis regulates human T cell function. J Immunol 188(8):3869\u20133875 e-pub ahead of print 2012\/03\/20. https:\/\/doi.org\/10.4049\/jimmunol.1103627","journal-title":"J Immunol"},{"issue":"10","key":"6304_CR45","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1111\/cas.13324","volume":"108","author":"J Gao","year":"2017","unstructured":"Gao J, Zheng Q, Xin N, Wang W, Zhao C (2017) CD155, an onco-immunologic molecule in human tumors. Cancer Sci 108(10):1934\u20131938 e-pub ahead of print 2017\/07\/22. https:\/\/doi.org\/10.1111\/cas.13324","journal-title":"Cancer Sci"},{"issue":"25","key":"6304_CR46","doi-asserted-by":"publisher","first-page":"17647","DOI":"10.1074\/jbc.M114.572420","volume":"289","author":"M Li","year":"2014","unstructured":"Li M, Xia P, Du Y, Liu S, Huang G, Chen J et al (2014) T-cell Immunoglobulin and ITIM domain (TIGIT) receptor\/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via beta-arrestin 2-mediated negative signaling. J Biol Chem 289(25):17647\u201317657 e-pub ahead of print 2014\/05\/13. https:\/\/doi.org\/10.1074\/jbc.M114.572420","journal-title":"J Biol Chem"},{"issue":"1","key":"6304_CR47","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41423-018-0168-y","volume":"16","author":"P Kucan Brlic","year":"2019","unstructured":"Kucan Brlic P, Lenac Rovis T, Cinamon G, Tsukerman P, Mandelboim O, Jonjic S, Targeting (2019) PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol 16(1):40\u201352. https:\/\/doi.org\/10.1038\/s41423-018-0168-y. e-pub ahead of print 2018\/10\/03","journal-title":"Cell Mol Immunol"},{"key":"6304_CR48","doi-asserted-by":"publisher","first-page":"1104771","DOI":"10.3389\/fimmu.2023.1104771","volume":"14","author":"X Chi","year":"2023","unstructured":"Chi X, Luo S, Ye P, Hwang WL, Cha JH, Yan X et al (2023) T-cell exhaustion and stemness in antitumor immunity: characteristics, mechanisms, and implications. Front Immunol 14:1104771. https:\/\/doi.org\/10.3389\/fimmu.2023.1104771. e-pub ahead of print 2023\/03\/10","journal-title":"Front Immunol"},{"key":"6304_CR49","doi-asserted-by":"publisher","unstructured":"Chauvin JM, Zarour HM (2020) TIGIT in cancer immunotherapy. J Immunother Cancer 8(2). https:\/\/doi.org\/10.1136\/jitc-2020-000957. e-pub ahead of print 2020\/09\/10","DOI":"10.1136\/jitc-2020-000957"},{"key":"6304_CR50","doi-asserted-by":"publisher","first-page":"871085","DOI":"10.3389\/fonc.2022.871085","volume":"12","author":"T Annese","year":"2022","unstructured":"Annese T, Tamma R, Ribatti D (2022) Update in TIGIT Immune-Checkpoint role in Cancer. Front Oncol 12:871085 e-pub ahead of print 2022\/06\/04. https:\/\/doi.org\/10.3389\/fonc.2022.871085","journal-title":"Front Oncol"},{"issue":"22","key":"6304_CR51","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research N, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ et al (2013) Genomic and epigenomic landscapes of adult de Novo acute myeloid leukemia. N Engl J Med 368(22):2059\u20132074 e-pub ahead of print 2013\/05\/03. https:\/\/doi.org\/10.1056\/NEJMoa1301689","journal-title":"N Engl J Med"},{"key":"6304_CR52","doi-asserted-by":"publisher","unstructured":"Bagger FO, Sasivarevic D, Sohi SH, Laursen LG, Pundhir S, Sonderby CK et al (2016) BloodSpot: a database of gene expression profiles and transcriptional programs for healthy and malignant haematopoiesis. Nucleic Acids Res; 44(D1): D917-924. e-pub ahead of print 2015\/10\/29; https:\/\/doi.org\/10.1093\/nar\/gkv1101","DOI":"10.1093\/nar\/gkv1101"},{"key":"6304_CR53","doi-asserted-by":"publisher","unstructured":"Bagger FO, Kinalis S, Rapin N (2019) BloodSpot: a database of healthy and malignant haematopoiesis updated with purified and single cell mRNA sequencing profiles. Nucleic Acids Res; 47(D1): D881-D885. e-pub ahead of print 2018\/11\/06; https:\/\/doi.org\/10.1093\/nar\/gky1076","DOI":"10.1093\/nar\/gky1076"},{"key":"6304_CR54","doi-asserted-by":"publisher","unstructured":"Abaza Y, Zeidan AM (2022) Immune checkpoint Inhibition in acute myeloid leukemia and myelodysplastic syndromes. Cells 11(14) e-pub ahead of print 2022\/07\/28. https:\/\/doi.org\/10.3390\/cells11142249","DOI":"10.3390\/cells11142249"},{"key":"6304_CR55","doi-asserted-by":"publisher","unstructured":"Valhondo I, Hassouneh F, Lopez-Sejas N, Pera A, Sanchez-Correa B, Guerrero B et al (2020) Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T cell subsets in patients with acute myeloid leukemia. Cancers (Basel) 12(8) e-pub ahead of print 2020\/08\/09. https:\/\/doi.org\/10.3390\/cancers12082171","DOI":"10.3390\/cancers12082171"},{"key":"6304_CR56","doi-asserted-by":"publisher","unstructured":"Yue J, Li J, Ma J, Zhai Y, Shen L, Zhang W et al (2023) Myeloid-derived suppressor cells inhibit natural killer cells in myelodysplastic syndromes through the TIGIT\/CD155 pathway. Hematology; 28(1): 2166333. e-pub ahead of print 2023\/01\/19; https:\/\/doi.org\/10.1080\/16078454.2023.2166333","DOI":"10.1080\/16078454.2023.2166333"},{"key":"6304_CR57","doi-asserted-by":"publisher","unstructured":"Meng F, Li L, Lu F, Yue J, Liu Z, Zhang W et al (2020) Overexpression of TIGIT in NK and T Cells Contributes to Tumor Immune Escape in Myelodysplastic Syndromes. Front Oncol; 10: 1595. e-pub ahead of print 2020\/09\/10; https:\/\/doi.org\/10.3389\/fonc.2020.01595","DOI":"10.3389\/fonc.2020.01595"},{"issue":"4","key":"6304_CR58","doi-asserted-by":"publisher","first-page":"e22859","DOI":"10.1002\/jcla.22859","volume":"33","author":"C Ampasavate","year":"2019","unstructured":"Ampasavate C, Jutapakdee W, Phongpradist R, Tima S, Tantiworawit A, Charoenkwan P et al (2019) FLT3, a prognostic biomarker for acute myeloid leukemia (AML): quantitative monitoring with a simple anti-FLT3 interaction and flow cytometric method. J Clin Lab Anal 33(4):e22859 e-pub ahead of print 2019\/02\/10. https:\/\/doi.org\/10.1002\/jcla.22859","journal-title":"J Clin Lab Anal"},{"key":"6304_CR59","doi-asserted-by":"publisher","unstructured":"Kaito Y, Hirano M, Futami M, Nojima M, Tamura H, Tojo A et al (2022) CD155 and CD112 as possible therapeutic targets of FLT3 inhibitors for acute myeloid leukemia. Oncol Lett; 23(2): 51. e-pub ahead of print 2022\/01\/08; https:\/\/doi.org\/10.3892\/ol.2021.13169","DOI":"10.3892\/ol.2021.13169"},{"key":"6304_CR60","doi-asserted-by":"publisher","unstructured":"Tang W, Xu J, Xu C (2023) Noncoding RNAs in the crosstalk between multiple myeloma cells and bone marrow microenvironment. Cancer Lett; 556: 216081. e-pub ahead of print 2023\/02\/05; https:\/\/doi.org\/10.1016\/j.canlet.2023.216081","DOI":"10.1016\/j.canlet.2023.216081"},{"issue":"2","key":"6304_CR61","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s11357-022-00698-x","volume":"45","author":"VS Urban","year":"2023","unstructured":"Urban VS, Cegledi A, Mikala G (2023) Multiple myeloma, a quintessential malignant disease of aging: a geroscience perspective on pathogenesis and treatment. Geroscience 45(2):727\u2013746 e-pub ahead of print 2022\/12\/13. https:\/\/doi.org\/10.1007\/s11357-022-00698-x","journal-title":"Geroscience"},{"key":"6304_CR62","doi-asserted-by":"publisher","first-page":"575609","DOI":"10.3389\/fimmu.2020.575609","volume":"11","author":"H Alfarra","year":"2020","unstructured":"Alfarra H, Weir J, Grieve S, Reiman T (2020) Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy. Front Immunol 11:575609 e-pub ahead of print 2020\/12\/12. https:\/\/doi.org\/10.3389\/fimmu.2020.575609","journal-title":"Front Immunol"},{"key":"6304_CR63","doi-asserted-by":"publisher","unstructured":"Lee BH, Kim JH, Kang KW, Lee SR, Park Y, Sung HJ et al (2022) PVR (CD155) expression as a potential prognostic marker in multiple myeloma. Biomedicines 10(5) e-pub ahead of print 2022\/05\/29. https:\/\/doi.org\/10.3390\/biomedicines10051099","DOI":"10.3390\/biomedicines10051099"},{"key":"6304_CR64","doi-asserted-by":"publisher","unstructured":"Cippitelli M, Stabile H, Kosta A, Petillo S, Lucantonio L, Gismondi A et al (2023) Role of NF-kappaB signaling in the interplay between multiple myeloma and mesenchymal stromal cells. Int J Mol Sci 24(3) e-pub ahead of print 2023\/02\/12. https:\/\/doi.org\/10.3390\/ijms24031823","DOI":"10.3390\/ijms24031823"},{"issue":"1","key":"6304_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00277-022-05058-5","volume":"102","author":"B Tanenbaum","year":"2023","unstructured":"Tanenbaum B, Miett T, Patel SA (2023) The emerging therapeutic landscape of relapsed\/refractory multiple myeloma. Ann Hematol 102(1):1\u201311 e-pub ahead of print 2022\/12\/04. https:\/\/doi.org\/10.1007\/s00277-022-05058-5","journal-title":"Ann Hematol"},{"key":"6304_CR66","doi-asserted-by":"publisher","unstructured":"Huh J (2012) Epidemiologic overview of malignant lymphoma. Korean J Hematol; 47(2): 92\u2013104. e-pub ahead of print 2012\/07\/12; https:\/\/doi.org\/10.5045\/kjh.2012.47.2.92","DOI":"10.5045\/kjh.2012.47.2.92"},{"key":"6304_CR67","doi-asserted-by":"publisher","unstructured":"Annibali O, Bianchi A, Grifoni A, Tomarchio V, Tafuri M, Verri M et al (2021) A novel scoring system for TIGIT expression in classic Hodgkin lymphoma. Sci Rep; 11(1): 7059. e-pub ahead of print 2021\/03\/31; https:\/\/doi.org\/10.1038\/s41598-021-86655-8","DOI":"10.1038\/s41598-021-86655-8"},{"key":"6304_CR68","doi-asserted-by":"publisher","unstructured":"Jiang VC, Hao D, Jain P, Li Y, Cai Q, Yao Y et al (2022) TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma. Mol Cancer; 21(1): 185. e-pub ahead of print 2022\/09\/27; https:\/\/doi.org\/10.1186\/s12943-022-01655-0","DOI":"10.1186\/s12943-022-01655-0"},{"issue":"8","key":"6304_CR69","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1158\/2159-8290.CD-21-1586","volume":"12","author":"Z Jackson","year":"2022","unstructured":"Jackson Z, Hong C, Schauner R, Dropulic B, Caimi PF, de Lima M et al (2022) Sequential Single-Cell transcriptional and protein marker profiling reveals TIGIT as a marker of CD19 CAR-T cell dysfunction in patients with Non-Hodgkin lymphoma. Cancer Discov 12(8):1886\u20131903. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1586. e-pub ahead of print 2022\/05\/14","journal-title":"Cancer Discov"},{"key":"6304_CR70","doi-asserted-by":"publisher","unstructured":"Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M et al (2017) TIGIT expressing CD4\u2009+\u2009T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia. Oncoimmunology; 7(1): e1371399. e-pub ahead of print 2018\/01\/04; https:\/\/doi.org\/10.1080\/2162402X.2017.1371399","DOI":"10.1080\/2162402X.2017.1371399"},{"issue":"7","key":"6304_CR71","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.31557\/APJCP.2022.23.7.2225","volume":"23","author":"F Hatefi","year":"2022","unstructured":"Hatefi F, Asgarian-Omran H, Hossein-Nataj H, Akbar A, Shekarriz R, Zaboli E et al (2022) Combined Blockade of PD-1 and TIGIT is not sufficient to improve the function of CD8\u2009+\u2009T-Cells in chronic lymphocytic leukemia. Asian Pac J Cancer Prev 23(7):2225\u20132231. https:\/\/doi.org\/10.31557\/APJCP.2022.23.7.2225. e-pub ahead of print 2022\/07\/29","journal-title":"Asian Pac J Cancer Prev"},{"key":"6304_CR72","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.282177","author":"F Arruga","year":"2023","unstructured":"Arruga F, Rubin M, Papazoglou D, Iannello A, Ioannou N, Moia R et al (2023) The Immunomodulatory molecule TIGIT is expressed by chronic lymphocytic leukemia cells and contributes to anergy. Haematologica. https:\/\/doi.org\/10.3324\/haematol.2022.282177. e-pub ahead of print 2023\/01\/20","journal-title":"Haematologica"},{"key":"6304_CR73","doi-asserted-by":"publisher","unstructured":"Ukrainskaya VM, Musatova OE, Volkov DV, Osipova DS, Pershin DS, Moysenovich AM et al (2023) CAR-tropic extracellular vesicles carry tumor-associated antigens and modulate CAR T cell functionality. Sci Rep; 13(1): 463. e-pub ahead of print 2023\/01\/11; https:\/\/doi.org\/10.1038\/s41598-023-27604-5","DOI":"10.1038\/s41598-023-27604-5"},{"key":"6304_CR74","doi-asserted-by":"publisher","unstructured":"Urena-Bailen G, Dobrowolski JM, Hou Y, Dirlam A, Roig-Merino A, Schleicher S et al (2022) Preclinical evaluation of CRISPR-Edited CAR-NK-92 cells for Off-the-Shelf treatment of AML and B-ALL. Int J Mol Sci 23(21) e-pub ahead of print 2022\/11\/12. https:\/\/doi.org\/10.3390\/ijms232112828","DOI":"10.3390\/ijms232112828"},{"key":"6304_CR75","doi-asserted-by":"publisher","unstructured":"Hunter R, Imbach KJ, Zhou C, Dougan J, Hamilton JAG, Chen KZ et al (2022) B-cell acute lymphoblastic leukemia promotes an immune suppressive microenvironment that can be overcome by IL-12. Sci Rep; 12(1): 11870. e-pub ahead of print 2022\/07\/14; https:\/\/doi.org\/10.1038\/s41598-022-16152-z","DOI":"10.1038\/s41598-022-16152-z"},{"issue":"19","key":"6304_CR76","doi-asserted-by":"publisher","first-page":"e2101447","DOI":"10.1002\/advs.202101447","volume":"8","author":"X Wang","year":"2021","unstructured":"Wang X, Chen Y, Li Z, Huang B, Xu L, Lai J et al (2021) Single-Cell RNA-Seq of T cells in B-ALL patients reveals an exhausted subset with remarkable heterogeneity. Adv Sci (Weinh) 8(19):e2101447 e-pub ahead of print 2021\/08\/09. https:\/\/doi.org\/10.1002\/advs.202101447","journal-title":"Adv Sci (Weinh)"},{"key":"6304_CR77","doi-asserted-by":"publisher","unstructured":"Kobayashi T, Ubukawa K, Fujishima M, Takahashi N (2021) Correlation between increased immune checkpoint molecule expression and refractoriness to blinatumomab evaluated by longitudinal T cell analysis. Int J Hematol; 113(4): 600\u2013605. e-pub ahead of print 2021\/01\/03; https:\/\/doi.org\/10.1007\/s12185-020-03047-w","DOI":"10.1007\/s12185-020-03047-w"},{"key":"6304_CR78","doi-asserted-by":"publisher","first-page":"103958","DOI":"10.1016\/j.cellimm.2019.103958","volume":"344","author":"X Zhang","year":"2019","unstructured":"Zhang X, Zhang H, Chen L, Feng Z, Gao L, Li Q (2019) TIGIT expression is upregulated in T cells and causes T cell dysfunction independent of PD-1 and Tim-3 in adult B lineage acute lymphoblastic leukemia. Cell Immunol 344:103958. https:\/\/doi.org\/10.1016\/j.cellimm.2019.103958. e-pub ahead of print 2019\/08\/05","journal-title":"Cell Immunol"},{"issue":"6","key":"6304_CR79","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N et al (2022) Tiragolumab plus Atezolizumab versus placebo plus Atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol 23(6):781\u2013792 e-pub ahead of print 2022\/05\/17. https:\/\/doi.org\/10.1016\/S1470-2045(22)00226-1","journal-title":"Lancet Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06304-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06304-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06304-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T06:11:10Z","timestamp":1745561470000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06304-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":79,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["6304"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06304-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article does not contain any studies with animals\/human participants performed by any of the authors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"No.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}